ArticleJournal of pain research2025
Esketamine as an Epidural Adjuvant for Postoperative Analgesia in Gynecological Malignancy Surgery: A Randomized Trial.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative Effectiveness of Single-Dose Epidural Esketamine versus Hydromorphone in Thoracic and Upper Abdominal Surgery: A Randomized Trial.Drug design, development and therapy · 2026Trial
- Esketamine Alleviates Neuropathic Pain and Inflammation via miR-153-3p/AKT3 in CCI Rats.Pain research & management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the efficacy of esketamine as an epidural adjuvant in mitigating postoperative pain, particularly following the discontinuation of epidural analgesia in patients undergoing open surgery for gynecological malignancies. Design: A randomized controlled trial. Methods: Eighty-eight patients were randomized to receive either esketamine (0.4 mg/kg) combined with sufentanil and ropivacaine (eskatamine group) or sufentanil and ropivacaine alone (control group) via patient-controlled epidural analgesia. Primary outcomes included pain scores on postoperative day 3, assessed using the numeric rating scale. Secondary outcomes included pain scores on postoperative days 1 to 4, Quality of Recovery-15 scores, rescue analgesic requirements, and adverse events. Results: The eskatamine group demonstrated a significant reduction in nocturnal pain intensity on postoperative day 2 compared with controls (median 3.0 vs 4.0, Conclusion: Esketamine, as an adjuvant in patient-controlled epidural analgesia, reduced nocturnal pain on postoperative day 2, shorten the moderate pain duration and lower rescue analgesics within 24 hours after the removal of analgesia device. However, it did not affect pain scores although less rescue analgesia was needed on postoperative day 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.